Chembio Diagnostics, Inc. (CEMI)’s Insider Neil Goldman Paid for 14,815 Shares of the Company; Affiliated Managers Group (AMG) Sentiment Is 0.91

Affiliated Managers Group, Inc., through its affiliates, operates as an asset management firm providing investment management services to mutual funds, institutional clients, and high net worth individuals in the United States. The company has market cap of $10.11 billion. It provides advisory or subadvisory services to mutual funds. It has a 15.12 P/E ratio. These funds are distributed to retail and institutional clients directly and through intermediaries, including independent investment advisors, retirement plan sponsors, broker-dealers, major fund marketplaces, and bank trust departments.

As reported in a report that’s submitted to the U.S. Security & Exchange Commission on February 13, 2018, Neil Goldman an insider in Chembio Diagnostics Inc and currently EVP & Chief Financial Officer, invested in shares worth $100,001 USD in the New York-based company. He acquired 14,815 new shares, at average $6.8 per share. Neil Goldman at present owns 0.12% of the Company’s total market capitalization with ownership of 14,815 shares. 

Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, makes, markets, and licenses rapid point-of-care diagnostic tests that detect infectious diseases. The company has market cap of $93.62 million. It offers rapid tests for the detection of HIV and syphilis antibodies. It currently has negative earnings. The company's products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a DPP HIV-Syphilis multiplex test for the detection of antibodies to HIV and syphilis; and a test for the detection of Hepatitis-C.

Analysts await Chembio Diagnostics, Inc. (NASDAQ:CEMI) to report earnings on March, 6. They expect $-0.12 earnings per share, up 42.86% or $0.09 from last year’s $-0.21 per share. After $-0.05 actual earnings per share reported by Chembio Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 140.00% negative EPS growth.

The stock increased 2.70% or $0.2 during the last trading session, reaching $7.6. About 93,256 shares traded or 3.85% up from the average. Chembio Diagnostics, Inc. (NASDAQ:CEMI) has declined 22.25% since February 14, 2017 and is downtrending. It has underperformed by 38.95% the S&P500.

Investors sentiment increased to 1.25 in 2017 Q3. Its up 0.45, from 0.8 in 2017Q2. It is positive, as 5 investors sold Chembio Diagnostics, Inc. shares while 3 reduced holdings. 6 funds opened positions while 4 raised stakes. 4.18 million shares or 10.95% more from 3.77 million shares in 2017Q2 were reported. Wellington Mngmt Llp holds 0% or 918,535 shares in its portfolio. Bridgeway Cap invested in 80,100 shares or 0.01% of the stock. Wells Fargo And Mn reported 76,250 shares. Acuta Cap Ptnrs Ltd Com stated it has 1.91% in Chembio Diagnostics, Inc. (NASDAQ:CEMI). Perkins Cap Mgmt holds 35,500 shares or 0.23% of its portfolio. Fny Managed Accounts Limited Liability Company accumulated 2,784 shares or 0.02% of the stock. Pennsylvania-based Vanguard Group Inc has invested 0% in Chembio Diagnostics, Inc. (NASDAQ:CEMI). Royal Bank & Trust Of Canada accumulated 9 shares. Northern holds 0% or 18,733 shares. Blackrock Inc reported 33,249 shares. Phocas owns 20,000 shares or 0% of their US portfolio. The New York-based Morgan Stanley has invested 0% in Chembio Diagnostics, Inc. (NASDAQ:CEMI). Geode Cap Mngmt Limited Liability Corp has 49,468 shares. Thompson Davis Inc owns 0.02% invested in Chembio Diagnostics, Inc. (NASDAQ:CEMI) for 1,500 shares. Benchmark Advisors owns 32,900 shares.